Home

About

Advanced Search

Browse by Discipline

Scientific Societies

E-print Alerts

Add E-prints

E-print Network
FAQHELPSITE MAPCONTACT US


  Advanced Search  

 
The Case for QALY's: US Decision-Making for Pharmaceuticals
 

Summary: The Case for QALY's: US Decision-
Making for Pharmaceuticals
Disadvantages?
Christopher Leibman
Sr. Director Pharmacoeconomics
Elan Pharmaceuticals
What's wrong with QALYs, they seem so nice?
Apologies to R. Townsend
& Koala Bears
What's Wrong with QALY's - Common Criticisms
Historically cost-utility analysis was used to value
programs with widely different outcomes often mis-
applied
Whose preferences should be used?
Can the stages of disease be adequately depicted so
utilities can be determined? Measurement is
problematic
May not ethically distribute healthcare often left with
discussing appropriate thresholds
Methods...Others...

  

Source: Abagyan, Ruben - School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego

 

Collections: Biology and Medicine